Skip to main content
| News

VectivBio secures investments totaling 110 million dollars

19.10.2020

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing investors. With this fresh funding, the Basel-based company intends to further develop its drug to treat short bowel syndrome.

The new investors Surveyor Capital, Cormorant Capital and Eventide Asset Management, in addition to existing investors such as the Basel-based Versant Ventures, have provided VectivBio AG with a fresh capital injection totaling 110 million US dollars. According to a press release, the biotechnology firm, which is headquartered in Basel, intends to put this funding towards the further development of its leading product candidate by the name of apraglutide as well as to drive forward commercialization activities and develop additional product candidates.

VectivBio develops innovative drugs aimed at treating rare diseases. The lead product candidate apraglutide serves to combat short bowel syndrome, which is where a section of the small intestine is missing. Symptoms of short bowel syndrome can be the result of congenital abnormalities or emerge in the wake of surgical interventions. Patients suffering from short bowel syndrome require the artificial, intravenous delivery of essential nutrients, a process which can take up to 15 hours per day, according to the press release issued by VectivBio. By administering apraglutide, the aim is to enable to the patient’s body to absorb fluid nutrients more effectively in addition to allowing some nutrients to be taken orally. The fresh capital should allow a Phase III clinical trial to be realized for apraglutide. Moreover, through this process, the company hopes to accordingly be in a position to launch a best-in-class therapy, according to Luca Santarelli, CEO at VectivBio, in the press release.

Santarelli was also previously CEO at the Basel-based Therachon AG, which was taken over last year by Pfizer. As is the case now at VectivBio, Versant Ventures was involved with Therachon as a founding investor. “We have worked with Luca from the beginning and are excited about the progress we’re making into VectivBio’s next chapter”, comments Tom Woiwode, Managing Director at Versant Ventures and Chairman of the Board of Directors at VectivBio, in the press release.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Novartis investing 100 million Swiss francs in new biologics center

The pharmaceutical company Novartis is investing a sum of 100 million Swiss francs in a new competence center for biologics...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest

Official opening of the competence center uptownBasel

uptownBasel celebrated its official opening. Technology companies such as Bouygues and Vinci Energies are already occupying the first building of...

Read More
Basel Area Business & Innovation, Innovation, Life Sciences / biotech, Medtech, Switzerland Innovation Park

Eight startups from Basel Area feature in TOP 100 Swiss Startups

Among the most promising startups in Switzerland eight companies from Basel Area's startup ecosystem have been named. They are some...

Read More
Basel Area Business & Innovation, Invest, Life Sciences / biotech

Roche opens tallest building in Switzerland

Roche has inaugurated a new office building with 3,200 positions in Basel. Standing 205 meters high, Building 2 is the...

Read More
Basel Area Business & Innovation, Innovation, Medtech, Switzerland Innovation Park

DayOne Tech supports three medtech startups

DayOne, the healthcare innovation initiative from Basel Area Business & Innovation, has started its medtech accelerator in the canton of...

Read More
Basel Area achieves milestone with settling of LifeMine
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel Area achieves milestone with settling of LifeMine

Life sciences company LifeMine Therapeutics from the USA has established its European headquarters in the Basel Area. With this, Basel...

Read More
1 2 3 57

Do you have a question? We'd like to hear from you.